Reckitt Benckiser Group (OTCMKTS:RBGLY - Get Free Report) was downgraded by analysts at Barclays from an "overweight" rating to an "equal weight" rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports.
Several other research firms also recently weighed in on RBGLY. Sanford C. Bernstein downgraded shares of Reckitt Benckiser Group from a "strong-buy" rating to a "hold" rating in a report on Monday, November 4th. Hsbc Global Res upgraded Reckitt Benckiser Group from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, December 11th. Finally, HSBC raised Reckitt Benckiser Group from a "hold" rating to a "buy" rating in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Reckitt Benckiser Group has an average rating of "Buy".
Read Our Latest Stock Report on Reckitt Benckiser Group
Reckitt Benckiser Group Price Performance
OTCMKTS:RBGLY traded down $0.11 during midday trading on Tuesday, hitting $13.08. 335,711 shares of the company were exchanged, compared to its average volume of 333,911. The company has a debt-to-equity ratio of 0.97, a current ratio of 0.69 and a quick ratio of 0.47. Reckitt Benckiser Group has a fifty-two week low of $10.24 and a fifty-two week high of $15.03. The company has a fifty day simple moving average of $12.31 and a 200 day simple moving average of $12.03.
About Reckitt Benckiser Group
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Read More
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
